Highlights: Commerce Resources confirms significant niobium mineralization with 122.5m at 0.62% Nb2O5 from near surface at the Mallard Prospect, Eldor Property, located within 2 km of the Company's globally significant Ashram Rare-Earth and Fluorspar Deposit, Quebec, Canada. Core assay results from the first seven (7) drill holes of the 2024 program, which targeted the Mallard Prospect and Spoke Target, are reported herein: Mallard Prospect: 122.5 m at0.62% Nb2O5 and 6.4% P2O5 (EC24-208), including, 12.0 m at 0.82% Nb2O5 and 7.5% P2O5 7.5 m at 1.01% Nb2O5 and 12.3% P2O5 15.5 m at 0.62%Nb2O5, 360 ppm Ta2O5, and 6.6% P2O5 (EC24-211), including, 8.1 m at 0.79% Nb2O5, 439 ppm Ta2O5, and 7.7% P2O5 42.9 m at 0.60% Nb2O5 and 7.1% P2O5 (EC24-211), including, 2.9 m at 1.13% Nb2O5 and 12.7% P2O5 24.0 m at 0.69% Nb2O5 and6.2% P2O5 (EC24-210) Spoke Target: 27.5 m at 0.60% Nb2O5 and 8.7% P2O5 (EC24-212) 17.9 m at 0.66% Nb2O5 and 5.2% P2O5 (EC24-213) 21.3 m at 0.60% Nb2O5 and 5.8% P2O5 (EC24-213) The 2024 drill program of twenty-nine (29) NQ-size drill holes totalling 8,253 m has now concluded, with remaining drill core assays anticipated within Q4 of 2024.
RBC Capital has recently adjusted its outlook on Abbott Laboratories (ABT, Financial), increasing its target price from $125 to $130. The firm continues to maintain an "Outperform" rating for the company, indicating a strong confidence in its potential for growth in the market.
British oil giant BP advanced efforts to adjust its business plans to make itself more competitive with peer companies Monday, announcing it will abandon a goal of reducing its equity oil production by 2030. Originally set in 2020 at a 40% reduction by former CEO Bernard Looney, current BP management led by CEO Murray Auchincloss had reduced the goal in January to a 25% target.
BP has decided to abandon its goal of reducing oil and gas production by 2030, as the company shifts its focus. BP's CEO, Murray Auchincloss, is working on revamping the company's energy transition strategy to rebuild investor confidence.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
BP (BP) reportedly has given up on its goal to cut oil and gas output by 2030, as the British energy giant's chief executive seeks to build back investor confidence in the company.
Target has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.9% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources.
Chord Energy, formed from the merger of Oasis and Whiting Petroleum, recently acquired Enerplus, enhancing its strength despite a temporarily weak current ratio. Trading below book value with a P/E ratio of 7.43, Chord Energy offers strong value, especially given its secure production area in the Williston Basin. The company's success hinges on oil and gas prices, with potential risks from geopolitical tensions, localized issues, and exploration uncertainties.
Rivian tumbled Friday as the EV startup reported third-quarter deliveries below consensus and lowered its full-year production goal.
Target (TGT) closed the most recent trading day at $150.40, moving -1.18% from the previous trading session.
Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide.
Wells Fargo issued a rare price target cut for the Mag 7 company, citing caution on Google search growth amid regulatory headlines. However, Caroline Woods notes bullishness from other analysts which paint a different picture of Alphabet (GOOGL).